Semaglutide, also known as Wegovy and Ozempic, is the first and only GLP-1 (glucagon-like peptide) FDA-approved weight loss medication
Importantly, no participants experienced clinically significant hypoglycemia, medullary thyroid cancer, or C-cell hyperplasia, consistent with the known safety profile of incretin therapies
Despite the intensity of the guesses, there is no public statement or credible source linking Michelle Obama to Ozempic or any other such medication
However, meaningful, clinically significant weight loss typically defined as 5% of baseline body weight, a threshold referenced in NICE guidance on the management of overweight and obesity generally becomes apparent between weeks 8 and 12 , particularly as the dose is gradually escalated according to the trial protocol